Oct. 13 (Thu.) ,2016 15:30-17:00

Annex Hall

Simultaneous Interpretation

Is Recombinant Vaccine Similar to Bio-pharmaceuticals?
~ Common and Different Points ~

The technology platform and new adjuvants essential to create innovative vaccines will be reviewed and the potential issues for the future vaccine development will be discussed.
The differences between biopharmaceuticals and conventional vaccines will be lectured showing recombinant protein vaccine as an example.
The key regulatory points relating to the quality assessment of biopharmaceuticals and vaccines will be explained. 
Finally, the important and urgent issues to promote the development of innovative biopharmaceuticals and vaccines using new technology and to facilitate global developments as well as industry-government-academia efforts will be debated among panelists.


Kentaro Yoshimatsu

Vice Chairman, Biopharmaceutical Committee, JPMA


Norihito Ueda

Chairperson, Subcommittee on Vaccine Issues, Biopharmaceutical Committee, JPMA

Recombinant Vaccines Made Using BEVS

Fumihisa Nakata

Director, UMN Pharma

Quality Review of Biotherapeutics

Futaba Honda

Deputy Director, Office of Cellular and Tissue-based Products, Pharmaceuticals & Medical Devices Agency

Close Window